Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 835680, 8 pages
Review Article

Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies

Institute of Developmental Biology and Cancer UMR 6543, University of Nice Sophia Antipolis, CNRS, Centre Antoine Lacassagne, 06189 Nice, France

Received 16 November 2009; Accepted 5 January 2010

Academic Editor: Arkadiusz Dudek

Copyright © 2010 Renaud Grépin and Gilles Pagès. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Tumour angiogenesis, described by Folkman in the early seventies, is an essential, complex, and dynamic process necessary for the growth of all solid tumours. Among the angiogenic factors secreted by the tumour cells, the Vascular Endothelial Growth Factor (VEGF) is one of the most important. Most types of human cancer cells express elevated levels of this proangiogenic factor and its receptors. New molecules, called anti-angiogenic, are developed to impair VEGF pathway and tumour vasculature. Despite important results, the clinical benefits of anti-VEGF therapy are relatively modest and usually measured in weeks or months. Why following anti-angiogenic therapy do some patients respond transiently and then why does tumour grow again and disease progress and which compensatory mechanisms could explain the anti-angiogenic treatment failure?